搜索
IGC Pharma Inc
IGC添加自选
0.286USD
-0.013-4.18%
收盘 05/15, 16:00（美东）报价延迟15分钟
28.63M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.18%
5天
-8.04%
1月
-10.90%
6月
-20.11%
今年开始到现在
+1.63%
1年
-4.44%
TradingKey IGC Pharma Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
IGC Pharma Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名163/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.00。中期看，股价处于平稳状态。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
IGC Pharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
IGC Pharma Inc亮点
亮点风险
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
业绩增长期
公司处于发展阶段，最新年度总收入869.00K美元
估值低估
公司最新PE估值-6.13，处于3年历史低位
机构加仓
最新机构持股22.48M股，环比增加11.30%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值919.64K
活跃度增加
近期活跃度增加，过去20天平均换手率1.84
分析师目标
根据
2
位分析师
买入
评级
4.000
目标均价
+1237.79%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
IGC Pharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
IGC Pharma Inc简介
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
公司代码IGC
公司IGC Pharma Inc
CEOMukunda (Ram)
网址https://igcpharma.com/
相关品种
